Elad Jacoby

Elad Jacoby

Auto-generated profile, based on publicly available information

Elad Jacoby

Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2019 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
SFShalev Fried
Shalev Fried
AAAbraham Avigdor
Abraham Avigdor
BBBella Bielorai
Bella Bielorai
AMAmilia Meir
Amilia Meir
MBMichal J. Besser
Michal J. Besser
EJElad Jacoby
Elad Jacoby

2 July 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MRMeir Rozenbaum
Meir Rozenbaum
AMAmilia Meir
Amilia Meir
YAYarden Aharony
Yarden Aharony
OIOrit Itzhaki
Orit Itzhaki
JSJacob Schachter
Jacob Schachter
MBMichal Besser
Michal Besser
Autologous T cells engineered to express a chimeric antigen receptor (CAR) against the CD19 antigen are in the frontline of contemporary hemato-oncology therapies, leading to high remission rates in B-cell malignancies. Although effective, major obstacles involve the complex and costly individualized manufacturing process, and CD19 target antigen loss or modulation leading to resistant and relapse following CAR therapy. A potential solution for these limitations is the use of donor-derived γδT cells as a CAR backbone. γδT cells lack allogenecity and are safely used in haploidentical transplants. Moreover, γδT cells are known to mediate natural anti-tumor responses. Here, we describe a 14-day production process initiated from peripheral-blood mononuclear cells, leading to a median 185-fold expansion of γδ T cells with high purity (>98% CD3+ and >99% γδTCR+). CAR transduction efficacy of γδ T cells was equally high when compared to standard CAR-T cells (60.5 ± 13.2 and 65.3 ± 18.3%, respectively). CD19-directed γδCAR-T cells were effective against CD19+ cell lines in vitro and in vivo, showing cytokine production, direct target killing, and clearance of bone marrow leukemic cells in an NSG model. Multiple injections of γδCAR-T cells and priming of mice with zoledronate lead to enhanced tumor reduction in vivo. Unlike standard CD19 CAR-T cells, γδCAR-T cells were able to target CD19 antigen negative leukemia cells, an effect that was enhanced after priming the cells with zoledronate. In conclusion, γδCAR-T cell production is feasible and leads to highly pure and efficient effector cells. γδCAR-T cell may provide a promising platform in the allogeneic setting, and may target leukemic cells also after antigen loss.

22 November 2017 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
YYYinmeng Yang
Yinmeng Yang
MKM. Eric Kohler
M. Eric Kohler
CCChristopher D. Chien
Christopher D. Chien
CSChristopher T. Sauter
Christopher T. Sauter
EJElad Jacoby
Elad Jacoby
TFTerry J. Fry
Terry J. Fry
TCR engagement induces CD8 CAR T cell exhaustion and poor in vivo functionality in mice.

6 September 2018 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
EJElad Jacoby
Elad Jacoby
BBBella Bielorai
Bella Bielorai
AAAbraham Avigdor
Abraham Avigdor
OIOrit Itzhaki
Orit Itzhaki
DHDaphna Hutt
Daphna Hutt
ATAmos Toren
Amos Toren

15 May 2019 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
AKAnkit J. Kansagra
Ankit J. Kansagra
NFNoelle V. Frey
Noelle V. Frey
MBMerav Bar
Merav Bar
TLTheodore W. Laetsch
Theodore W. Laetsch
PCPaul A. Carpenter
Paul A. Carpenter
SHShahrukh Hashmi
Shahrukh Hashmi
On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

5 November 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
ATAna Alarcon Tomas
Ana Alarcon Tomas
JFJoshua A. Fein
Joshua A. Fein
SFShalev Fried
Shalev Fried
JFJessica R. Flynn
Jessica R. Flynn
SDSean M. Devlin
Sean M. Devlin
RSRoni Shouval
Roni Shouval